Polymorphisms in the AR gene may affect the efficacy of flutamide, an antiandrogen for prostate cancer, by altering its binding affinity and its antiandrogenic effects. Additionally, genetic variants in cytochrome P450 enzymes like CYP1A2 and CYP3A4 influence the metabolism of flutamide, impacting its effectiveness and toxicity by altering drug levels in the body.